Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization.

PloS one - 1 Jan 2022

Aman Alisha, Slob Eric A W, Ward Joey, Cullen Breda, Graham Nicholas, Lyall Donald M, Sattar Naveed, Strawbridge Rona J

Abstract excerpt

Prescription of PCSK9-inhibitors has increased in recent years but not much is known about its off-target effects. PCSK9-expression is evident in non-hepatic tissues, notably the brain, and genetic variation in the PCSK9 locus has recently been shown to be associated with mood disorder-related traits. We investigated whether PCSK9 inhibition, proxied by a genetic reduction in expression of PCSK9 mRNA, might have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Depressive Disorder, Major
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Mood Disorders

Share to Polymorphism, Single Nucleotide

Share to Proprotein Convertase 9

Share to Quantitative Trait Loci

Share to Ubiquitin Thiolesterase

Source

Open in PubMed Open full text

Identifiers

PMID: 36580462
DOI: 10.1371/journal.pone.0279381
PMCID: PMC9799310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization.PMID 36580462Read ↗

Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank.Semantic proximity Read ↗

Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization StudySemantic proximity Read ↗

Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank.Semantic proximity Read ↗

Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.Semantic proximity Read ↗

PCSK9 Inhibitors and Bipolar Disorder: A Drug Target Mendelian Randomization Study.Semantic proximity Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Deciphering the genetic underpinnings of neuroticism: A Mendelian randomization study of druggable gene targets.Semantic proximity Read ↗

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four AncestriesSemantic proximity Read ↗

Genetically Determined Levels of Serum Metabolites and Risk of Neuroticism: A Mendelian Randomization Study.Semantic proximity Read ↗

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.Semantic proximity Read ↗

Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) InhibitorsSemantic proximity Read ↗

Psychiatric traits and intracerebral hemorrhage: A Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.